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Abstract 
Background  Actinic keratosis (AK) severity is currently evaluated by subjective assessment of 
patients. 
Objectives  To develop and perform an initial pilot validation of a new easy-to-use quantitative tool 
for assessing AK severity on the head. 
Methods  The actinic keratosis area and severity index (AKASI) for the head was developed based on 
a review of other severity scoring systems in dermatology, in particular the psoriasis area and 
severity index (PASI). Initial validation was performed by 13 physicians assessing AK severity in 18 AK 
patients and 2 controls using a physician global assessment (PGA) and AKASI. To determine an AKASI 
score, the head was divided into four regions (scalp, forehead, left/right cheek ear, chin and nose). In 
each region, the percentage of the area affected by AKs was estimated, and the severities of three 
clinical signs of AK were assessed: distribution, erythema and thickness. 
Results  There was a strong correlation between AKASI and PGA scores (Pearson correlation 
coefficient: 0.86). AKASI was able to discriminate between different PGA categories: mean (SD) 
AKASI increased from 2.88 (1.18) for “light” to 5.33 (1.48) for “moderate”, 8.28 (1.89) for “severe”, 
and 8.73 (3.03) for “very severe” PGA classification. The coefficient of variation for AKASI scores was 
low and relatively constant across all PGA categories. 
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Conclusions  AKASI is proposed as a new quantitative tool for assessing AK severity on the head. It 
may be useful in the future evaluation of new AK treatments in clinical studies and the management 
of AK in daily practice. 
 
Introduction 
Actinic keratosis (AK) is a chronic and recurrent disease caused by long-term sun exposure, which is 
commonly seen in everyday dermatological practice.1,2 The prevalence of AK increases with age and 
is generally higher in men than women.3 Epidemiological studies have indicated that 40–60% of 
Australian adults and up to 38% of European adults have AK, and that the prevalence of the disease 
is rising.3,4 AKs are regarded as early in situ squamous cell carcinoma (SCC).5 They may progress into 
invasive SCC via progressive and sequential stages of keratinocyte intraepidermal neoplasia, with 
more recent evidence showing that AK I lesions are most commonly associated with invasive SCC, 
suggesting that early AK lesions may also directly transform into invasive disease.6 The risk of 
developing SCC rises with an increasing number of AK lesions.7 Since it is not possible to predict 
when and which AK lesions will transform into invasive SCC, and given that the entire area of sun-
exposed skin is affected by both clinical and subclinical disease resulting in field cancerisation, 
current treatment guidelines from the European Dermatology Forum and International League of 
Dermatological Societies advocate the need to treat all AK lesions and the entire affected field.8 
 The severity of individual clinical AK lesions is commonly graded using clinical and 
histological classification systems. The clinical classification system of Olsen et al. grades AK lesions 
according to their overall thickness.9 The histological classification system of Röwert-Huber et al. 
requires a biopsy and assesses lesions according to the extent of atypical keratinocytes in the 
epidermis.10 The main limitation of these scoring systems is that they only assess the severity of 
individual lesions and do not take into consideration the entire area affected by AK. In addition, 
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these scores do not give any information on the risk of AK lesions progressing to invasive SCC. 
Furthermore, it has recently been shown that these clinical and histological classification systems do 
not match, with over one third of lesions clinically classified as very thick and hyperkeratotic (Olsen 
grade 3) being shown histologically to be mild lesions with atypical keratinocytes limited to the 
lower third of the epidermis (i.e., AK I).11  
 Clinical studies of new AK therapies typically evaluate their efficacy based on AK lesion 
counts before and after treatment.12 The principal limitation of this approach is that in many cases 
AK lesions do not exist as discrete entities, but may rather coalesce across the affected field making 
it difficult, even for expert dermatologists, to accurately assess AK lesion numbers.13 
 A new scoring system to quantitatively evaluate the severity of AK across an entire affected 
area is therefore required. An AK severity scoring system could be used to define treatment goals, to 
evaluate the efficacy of new AK therapies and to compare the efficacy of different treatments across 
different clinical studies. The scoring system could also be used to assess the severity of AK in 
patients seen in the clinical setting, with cut-off thresholds being used to evaluate when to refer 
patients to specialists. An overall AK severity evaluation could also be used to tailor the support 
provided to AK patients based on their individual disease needs and circumstances, and to 
determine whether a treatment has been of benefit or not. Consequently, the aim of this work was 
to develop and provide an initial pilot validation of a simple, quick and easy-to-use AK area and 
severity scoring system for potential use both in clinical studies and in clinical practice. 
Materials and methods 
Development of actinic keratosis area and severity index (AKASI) for the head 
AKASI was developed based on a review of other severity scoring systems in dermatology (e.g., 
atopic dermatitis14, acne15,16, psoriasis17, vitiligo18-20, scleroderma21, pemphigus vulgaris22, melasma23, 
uriticaria24). The authors identified the common characteristics of these scoring systems which 
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typically evaluate the extent of disease, the intensity or morphology of lesions, subjective symptoms, 
and other disease-related factors. Based on this review, the authors considered that the psoriasis 
area and severity index (PASI) was most suitable for adapting to assess AK severity. PASI takes into 
account both the extent of disease and the severity of three clinical signs: erythema, induration and 
desquamation.17 To develop AKASI, consideration was given to the key factors involved in the clinical 
presentation of AK that could be used to differentiate between disease severities. 
Briefly, for the calculation of an AKASI score (Table 1), the head was divided into four areas 
and each region was given a weighting based on its approximate relative size as follows: scalp 40%; 
forehead 20%; left cheek, ear, chin and nose 20%; right cheek, ear, chin and nose 20%. Each 20% 
area referred approximately to the size of one open hand. For each region, the percentage of the 
area affected by AKs (perceived as field cancerisation by sight and using touch to feel the skin) was 
estimated and a numerical value of 0 to 6 assigned. Then, the severities of three clinical signs of AK 
(distribution, erythema and thickness) were assessed on a scale from 0 (none) to 4 (maximum), as 
detailed in Table 1. An AKASI subscore was calculated for each of the four areas of the head, which 
were then added together to give a total AKASI score for the entire head. Total scores ranged from 0 
(no AK) to 18 (AK of the severest possible degree). SCCs, seborrheic keratosis and solar lentigo were 
not included in the AKASI evaluation. An example of an AKASI calculation is shown in Fig. 1. 
Pilot validation study 
Patients and controls 
Patients with a clinical diagnosis of AK were randomly selected from the outpatient service of a 
referral centre for skin disease (Andreas Sygros Hospital, Athens, Greece) over a period of two weeks 
prior to the evaluation day. Patients were eligible for inclusion if they had any AK on their head (face, 
scalp, ears), regardless of prior treatment. Control subjects without AK were also recruited from the 
same outpatient service.  
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
Physicians 
The physicians who participated in this study were the authors of this manuscript as well as 
additional physicians recruited from the Athens region. The latter physicians had to be board-
certified dermatologists, could work in a hospital or office setting, and included physicians with 
different expertise in managing patients with AKs. 
 
Study design and evaluations 
The key objectives of the pilot validation study were to evaluate the correlation of AKASI with a 
physician global assessment (PGA) of AK, and to determine whether PGA categories can be 
differentiated by ranges of AKASI scores. The validation study was held at Andreas Sygros Hospital 
Athens, Greece on 21 May 2016. Ethics approval for the study was obtained from the Scientific and 
Ethics Committee of Andreas Sygros Hospital. 
 
An initial 30-minute training on AKASI was provided by TD and the physician participants 
were provided with a handout containing detailed instructions on AKASI (Supporting Information). 
Patients were assigned to separate examination rooms in the hospital. Physicians were randomly 
assigned to a starting room and proceeded to examine the individual patients in a pre-defined room-
to-room sequence. The physicians marked case report forms for the PGA score using the following 
categories: “None”, “Light”, “Moderate”, “Severe”, “Very severe”. The same case report forms were 
used to record scores for each of the components of AKASI. 
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Statistical analyses 
The correlation between AKASI and PGA was evaluated by Pearson correlation coefficient. 
Correlations between AKASI area subscores and AKASI component subscores with PGA were also 
calculated. The relationship between AKASI and PGA scores was further explored by plotting AKASI 
values against each PGA category from each dataset and by determining the respective AKASI 
distribution parameters (mean, median, 0.1 quantile, 0.9 quantile). Means, standard deviations and 
coefficients of variation for PGA and AKASI were calculated for each patient to examine interrater 
variation. Statistical analyses were carried out using MS-Access and MS-Excel. 
 
Results 
Patients and physicians 
Eighteen AK patients (mean age [range]: 73 years [60–80]; 10 men and 8 women) and two controls 
without AK (62-year old man and 70-year old woman) participated in this study. The mean (SD) PGA 
score was 0.08 (0.27) for the controls and 1.74 (0.80) for the patients. The mean (SD) AKASI score 
was 0.11 (0.38) for the controls and 4.75 (2.51) for the patients.  
 In total, 13 physicians participated in this study, including the 6 authors and 7 dermatologists 
from Athens. 
 
Correlation of AKASI with PGA 
The Pearson correlation coefficient for all physicians between AKASI and PGA (0.86) indicates that 
these measures of AK severity were strongly correlated (Tables 2 and 3). Out of the individual areas 
of the head, the correlation between AKASI and PGA was greatest for the forehead (Pearson 
correlation coefficient: 0.72) and lowest for the scalp (0.49; Table 2). There was a strong relationship 
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between all of the individual components of AKASI and PGA (distribution: 0.79; erythema: 0.84; 
thickness: 0.84; area score: 0.79; Table 3). AKASI subscores for the individual areas of the head were 
only weakly correlated with each other (Pearson correlation coefficient: 0.16–0.55), whereas the 
correlation between the individual component subscores was higher (0.73–0.86). 
 As shown in Fig. 2, AKASI was clearly able to discriminate between different PGA categories. 
The mean (SD) AKASI increased from 2.88 (1.18) for a PGA classification of “light” to 5.33 (1.48) for a 
PGA classification of “moderate”, 8.28 (1.89) for a PGA classification of “severe”, and 8.73 (3.03) for 
a PGA classification of “very severe”. The coefficient of variation for AKASI scores was low and 
relatively constant across all PGA categories. 
 
 The use of AKASI is illustrated with an example 67-year old male patient with Fitzpatrick Skin 
Type II. This patient was judged to have severe AK according to the PGA and had an AKASI score of 
9.0 (Fig. 1). 
 
 The variations of PGA and AKASI scores for each patient/control in the study are shown in 
Table S1 in the Supporting Information. For AK patients, the coefficient of variation for PGA (0.46) 
and AKASI (0.53) scores were similar, as were the coefficients of variation for the controls (3.53 and 
3.57, respectively).  
Discussion 
To our knowledge, the AKASI scoring system presented here represents the first attempt to 
quantitatively assess the severity of AK across an entire affected field, in this case the head. AKASI 
addresses the unmet need for a more accurate scoring system to assess the severity of AK, 
measuring both the area affected by actinic damage and three signs of AK lesions (distribution, 
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erythema and thickness), which were chosen due to their clinical relevance and potential for 
variation. Four areas of the head (scalp, forehead, left face, right face) were given weighting in the 
total AKASI score based on their approximate relative sizes. We hope that AKASI will become the 
standard way of assessing the severity of AK both in clinical studies of new treatments as well as in 
daily clinical practice.  
 AKASI was developed based on similar principles to PASI. Both systems take into 
consideration the extent of disease based on the size of the affected area calculated using the “rule 
of nine”, as well as the severity of clinical signs which are specific to the respective diseases.17 The 
resemblance of AKASI to PASI, a well-established measure which has been used by dermatologists 
for many years, is a key advantage of our new AK scoring system, which may help to facilitate uptake 
by practicing dermatologists. Given the small number of AK experts and general dermatologists in 
this study, it was not possible to meaningfully analyse whether the AKASI scores correlated 
differently to PGA scores according to the physicians’ level of AK expertise. However, we anticipate 
that dermatologists with differing levels of expertise in diagnosing and treating AK should be able to 
incorporate the use of AKASI into their daily clinical practice after only 30 minutes of training using 
clinical images. 
 
 Clinical studies of new AK treatments need to accurately quantify and compare the severity 
of disease before and after the intervention. The primary endpoint commonly used in investigations 
of new AK treatments is the complete clearance rate of lesions. Although this end point is easy to 
measure and detect, it is often challenging to achieve, may be confounded by the appearance of 
subclinical lesions during treatment, and most patients and physicians would consider a reduction in 
lesions as treatment success.12,25 The disease severity assessment provided by AKASI may be 
clinically more relevant than assessing whether or not a treatment clears all of a patient’s AK lesions.  
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Other endpoints in clinical studies are based on counting AK lesions before and after 
treatment. Lesion counting was avoided in the development of AKASI, since it is unreliable and not 
reproducible,13,26,27 and does not take into account the disease pathophysiology with actinic damage 
across the entire sun-exposed area.28 Lesion counting is particularly challenging in patients with 
severe photodamage in which contiguous AKs may coalesce into large areas of inflamed and sun-
damaged skin.3 Instead, AKASI assesses the percentage of the head area that is affected by actinic 
damage, as well as the distribution of AK lesions, with severity defined according to whether the 
lesions are isolated, clustered or coalescent. 
 The assessments which a physician needs to make to calculate an AKASI score are easy to 
learn, simple and quick to perform, and therefore suitable for assessing disease severity in clinical 
studies and daily practice. Following initial training, we estimate that a physician can complete the 
AKASI evaluations in 2–5 minutes. The evaluation involves assessing the thickness of AK lesions by 
touch, which is important since early AK is sometimes only palpable but not visible. Moreover, the 
possible different distribution of AK on the left/right facial sides, is not influencing the score, since 
both facial sides are evaluated. 
 The results of the pilot validation study showed that AKASI and PGA scores were highly 
correlated. Each of the individual components of AKASI (area, distribution, erythema and thickness) 
was strongly correlated to PGA. This is encouraging and is in contrast to a comparison of PASI with a 
PGA, in which the area scores were more highly correlated with PGA than were scores for erythema, 
induration and desquamation.29 Of the individual head areas, the correlation of the AKASI subscore 
for the forehead and PGA was the strongest, and the scalp and PGA was the weakest. The weaker 
correlation of scalp AKASI subscores and PGA may be because it is more difficult to assess the area 
affected by AK and the characteristics of AK lesions if they are located between hairs. AKs on the 
scalp may have been more commonly categorised as “isolated” rather than “confluent” decreasing 
the AKASI score and creating the difference between AKASI and PGA, suggesting that we need to 
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refine the initial training for this area to make the distinction between distribution scores clearer. 
The pilot validation study results also demonstrate the potential of AKASI scores to classify patients 
into different categories of AK severity, thereby facilitating the appropriate selection of lesion- 
versus field-directed treatments. 
 A limitation of this work was the number of physicians and patients that were used to 
validate AKASI. Future studies could further validate AKASI in larger populations of patients from 
different countries with different skin types. Subsequent studies could also include larger numbers 
of physicians and investigate their opinions on the ease of use of this new AK severity scoring 
system. AKASI was initially developed for the head area (i.e., face and scalp) since this is where the 
disease most commonly presents. The AKASI for the head area could be adapted for use on other 
areas of the body affected by AK such as the limbs and trunk. Moreover, the different area sub-
scores could be separately accounted in clinical trials, in consideration of varying response rates to 
AK treatments at different anatomical sites and of the targeted anatomical area. Investigations 
which evaluate the use of AKASI in clinical studies of new therapeutic agents for AK will also be 
informative. As data on AKASI accumulate, we hope to be able to provide discrete score ranges 
which correspond to mild, moderate and severe disease, as well as score reductions which 
constitute a clinically meaningful response, similar to those used for PASI (e.g., PASI 75; PASI 90). 
AKASI thresholds could be used as inclusion criteria in clinical studies of AK treatments, which would 
be more precise than using AK lesion counts or Olsen lesion classification. Many clinical studies 
currently exclude patients with Olsen grade 3 lesions since it is assumed that these have the highest 
risk of progression to SCC. However, recent evidence shows that only 14% of Olsen grade 3 lesions 
have severe atypia of the full thickness of the epidermis (i.e., AK III) questioning the relevance of this 
study exclusion criterion.11 Anyway, since the severity of AK and actinic damage is dependent on 
patient’s condition, severity threshold should be adapted to target population, i.e. immune-
compromised patients should be considered “severe” also for lower scores due to the increased risk 
to develop SCC. 
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 In conclusion, AKASI is proposed as a new quantitative tool for assessing the severity of AK 
on the head, which is easy to learn and is anticipated to prove useful in the future evaluation of new 
AK treatments in clinical studies as well as being of benefit to the diagnosis and management of AK 
in daily dermatological practice. 
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Figure Legends 
Figure 1. Example patient illustrating the use of AKASI. Clinical photographs of (A) the scalp; (B) 
forehead; (C) left cheek, ear, chin & nose; (D) right cheek, ear, chin & nose; and (E) completed AKASI. 
Figure 2. Distribution of AKASI scores versus PGA categories. 
AKASI, Actinic Keratosis Area and Severity Index; PGA, Physician’s Global Assessment. 
 
 
Table 1. Actinic Keratosis Area and Severity Index (AKASI): Definitions and coefficients/scores for 
calculation. 
Head area Description Coefficient 
Scalp Upper part of the forehead, from the 
detectable/supposed hair-line, parietal and occipital 
areas = 40% of the total area 
x0.4 
Forehead Forehead = 20% of the total area x0.2 
Left face Including cheek, ear, chin and nose = 20% of the 
total area 
x0.2 
Right face Including cheek, ear, chin and nose = 20% of the 
total area 
x0.2 
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Area extent 
Parameter Description Score 
Extent of sun-damaged 
skin 
Evaluation of sun-damage extent, considering skin 
alteration characteristic of field cancerisation 
Squamous cell carcinoma, seborrheic keratosis, solar 
lentigo are excluded 
0% = 0 
1–9% = 1 
10–29% = 2 
30–49% = 3 
50–69% = 4 
70–89% = 5 
90–100% = 6 
Aspects of AK 
Parameter Description Score 
Distribution None 
No clinical AKs 
0 
 Isolated or scattered 
Isolated or scattered AKs surrounded by apparently 
normal-looking skin 
1 
 Clustered 
Several isolated AKs confined to small clusters up to 
25 cm2 
2 
 Clustered and confluent 
AKs insider the cluster (up to 25 cm2) are coalescing 
3 
 All confluent 
Lesions coalescing and not clearly distinguishable 
across large sun-affected area 
4 
Erythema* None 0 
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No erythema 
 Slight 
Light red 
1 
 Moderate 
Red, but not deep red 
2 
 Intense 
Very red 
3 
 Very intense 
Extremely red 
4 
Thickness† No palpability 
Not detectable by touch 
0 
 Just palpable 
Just noticeable by touch 
1 
 Clearly palpable 
Easy to detect by touch 
2 
 Thickened 
Thick and hyperkeratotic 
3 
 Very thickened 
Very thick and hyperkeratotic 
4 
*Only evaluate erythema related to AK; exclude erythema related to other dermatological 
conditions such as rosacea or from ongoing AK treatment. 
†Evaluated based on touch. 
The head is divided into four areas: scalp, forehead, left and right face. For each region, the 
percentage of the area affected by sun-damage is estimated and a score is assigned accordingly; and 
the distribution of AKs, the intensity of erythema, and thickness of the worst visible AK in that area 
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are considered. The sum of AK aspect scores are added to the Area Index and multiplied by the Area 
Coefficient to obtain a subscore for each area of the head. The sum of the four subscores 
corresponds to the AKASI (which ranges from 0, no lesion/no sun-damage, to 18, vast sun-damage 
and severe lesions). 
 
Table 2. Correlation between total AKASI score and subscores for the different regions of the head 
with PGA. 
 
PGA Scalp Forehead Left face Right face AKASI 
PGA 1 
     Scalp 0.49108 1 
    Forehead 0.72090 0.21601 1 
   Left face 0.71607 0.17223 0.61271 1 
  Right face 0.65218 0.15655 0.47267 0.55136 1 
 AKASI 0.86387 0.74171 0.70025 0.69174 0.65170 1 
 
AKASI, Actinic Keratosis Area and Severity Index; PGA, Physician’s Global Assessment. 
Data are Pearson correlation coefficients. 
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Table 3. Correlation of the total AKASI score and its different component subscores with PGA. 
  PGA Distribution Erythema Thickness Area AKASI 
PGA 1 
     Distribution 0.79052 1 
    Erythema 0.84449 0.78854 1 
   Thickness 0.84451 0.79248 0.86066 1 
  Area 0.78894 0.80723 0.73624 0.73318 1 
 AKASI 0.86387 0.87991 0.87008 0.90766 0.89389 1 
AKASI, Actinic Keratosis Area and Severity Index; PGA, Physician’s Global Assessment. 
Data are Pearson correlation coefficients. 
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Erythema
Most severe 
erythema: Moderate
SCORE: 2 Distribution:
Clustered and
conﬂuent
SCORE: 3 
Area affected:
About 35%
SCORE: 3 
(a) Scalp
Thickness
Most hyperkeratotic 
lesion: Clearly palpable
SCORE: 2 
(b) Forehead
Area affected:
About 25%
SCORE: 2
Erythema
Most severe 
erythema: Moderate
SCORE: 2 
Distribution:
Clustered and
conﬂuent
SCORE: 3 Thickness
Most hyperkeratotic 
lesion: Thickened
SCORE: 3
Area affected:
About 15%
SCORE: 2 
Distribution:
Isolated or 
scattered
SCORE: 1
Erythema
Most severe 
erythema: Moderate
SCORE: 2 
(c) Left cheek, ear, chin and nose
Thickness
Most hyperkeratotic 
lesion: Clearly palpable
SCORE: 2 
Folliculitis
Does not belong 
to AK
Area affected:
About 20%
SCORE: 2 
Distribution:
Isolated or 
scattered
SCORE: 1
(d) Right cheek, ear, chin and nose
Erythema
Most severe 
erythema: Moderate
SCORE: 2 
Thickness
Most hyperkeratotic 
lesion: Thickened
SCORE: 3
(e) Schematic form - Total score calculation 
Total score range from 0 to 18.
Score Scalp Forehead Left cheek, ear, 
chin and nose
Right cheek, ear, 
chin and nose
D (Distribution) 3 3 1 1
E (Erythema) 2 2 2 2
T (Thickness) 2 3 2 2
Sum of D+ E + T 7 8 5 6
% of affected area 35% 25% 15% 20%
Area score 3 2 2 2
Subtotal (Sum of D + E T + Area score) 10 10 7 8
Area coefficient x 0.4 x 0.2 x 0.2 x 0.2
Total score 4.0 2.0 1.4 1.6
Total Akasi 9.0
Area 0% 1-9% 10-29% 30-49% 50-69% 70-89% 90-100%
Score 0 1 2 3 4 5 6
Intensity Absent Mild Moderate Severe Very severe
Distribution None Isolated or 
scattered
Clustered Clustered and 
confluent
All confluent
Erythema None Slight Moderate Intense Very intense
Thickness No 
palpability
Just 
palpable
Clearly 
palpable
Thickened Very 
thickened
Score 0 1 2 3 4
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